Questcor Pharmaceuticals Inc Watch

from 8-K 104 pages Agreement and Plan of Merger by and Among Mallinckrodt PLC, Quincy Merger Sub, Inc. and Questcor Pharmaceuticals, Inc. Dated as of April 5, 2014

from 425 104 pages Agreement and Plan of Merger by and Among Mallinckrodt PLC, Quincy Merger Sub, Inc. and Questcor Pharmaceuticals, Inc. Dated as of April 5, 2014

from 425 104 pages Agreement and Plan of Merger by and Among Mallinckrodt PLC, Quincy Merger Sub, Inc. and Questcor Pharmaceuticals, Inc. Dated as of April 5, 2014

from 10-Q ~50 pages Asset Purchase Agreement

from 10-Q ~50 pages License Agreement

from 8-K 24 pages Assignment and Assumption Agreement Dated as of May 4, 2006 by and Between Questcor Pharmaceuticals, Inc., a California Corporation, “Purchaser” and Medpointe Healthcare Inc., a Delaware Corporation, “Seller”

from 10-K405 >50 pages Plan of reorganization, merger, acquisition or similar

from S-3/A 1 page Plan of reorganization, merger, acquisition or similar

from S-3/A 1 page Plan of reorganization, merger, acquisition or similar

from S-3/A 1 page Plan of reorganization, merger, acquisition or similar

from S-3 1 page Plan of reorganization, merger, acquisition or similar

from S-3 1 page Plan of reorganization, merger, acquisition or similar

from S-3 ~10 pages Plan of reorganization, merger, acquisition or similar

from S-3 1 page Consent of Ernst & Young Llp, Independent Auditors We Consent to the Reference to Our Firm Under the Caption "Experts" in the Registration Statement (Form S-3) and Related Prospectus of Cypros Pharmaceutical Corporation for the Registration of Shares of Its Common Stock and to the Incorporation by Reference Therein of Our Report Dated August 26, 1996, With Respect to the Financial Statements of Cypros Pharmaceutical Corporation Included in Its Annual Report (Form 10-K) for the Year Ended July 31, 1996, Filed With the Securities and Exchange Commission. Ernst & Young Llp San Diego, California December 4, 1996

from S-3 1 page Exhibit 5.1 May 8, 1996 Cypros Pharmaceutical Corporation 2714 Loker Avenue West Carlsbad, California 92008 Ladies and Gentlemen: You Have Requested Our Opinion With Respect to Certain Matters in Connection With the Filing by Cypros Pharmaceutical Corporation (The "Company") of a Registration Statement on Form S-3 (The "Registration Statement") With the Securities and Exchange Commission Covering the Offer and Sale of Up to Two Hundred Thousand (200,000) Shares of the Company's Common Stock, No Par Value, by a Certain Shareholder, as Described in the Registration Statement (The "Shares"). in Connection With This Opinion, We Have Examined the Registration Statement and Related Prospectus, Your Restated Articles of Incorporation, as Amended, Your Bylaws, as Amended and Such Other Documents, Records, Certificates, Memoranda and Other Instruments as We Deem Necessary as a Basis for This Opinion. We Have Assumed the Genuineness and Authenticity of All Documents Submitted to US as Originals, the Conformity to Originals of All Documents Submitted to US as Copies Thereof, and the Due Execution and Delivery of All Documents Where Due Execution and Delivery Are a Prerequisite to the Effectiveness Thereof. on the Basis of the Foregoing, and in Reliance Thereon, We Are of the Opinion That the Shares Are Validly Issued, Fully Paid, and Nonassessable. We Consent to the Reference to Our Firm Under the Caption "Legal Matters" in the Prospectus Included in the Registration Statement and to the Filing of This Opinion as an Exhibit to the Registration Statement. Very Truly Yours, Cooley Godward Castro Huddleson & Tatum By: M. Wainwright Fishburn, Jr